30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Adverse Drug Events
Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
Adverse Drug Events
Primary: Time to Intervention Once an ADE Alert Has Fired in CPRS — 6.8; 8 hours to intervention — p=0.6680
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
Adverse Drug Reaction
Primary: Absolute Number of ADE Reporting (Change Behavior of Health Professionals) — 215; 3 absolute number of adverse drug events
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Aging · Benzodiazepine Sedative Adverse Reaction · Anticholinergic Adverse Reaction
Primary: Change in Inappropriate Prescribing — 106; 145; 122 Participants — p=0.002
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) — 0.15; 0.00 percentage of participants
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
Interdisciplinary Communication · Management, Medication Therapy
Primary: Incident Rate for Communication Events — 47.6; 34.74; 34.07 mean events per observation — p=0.01
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
HIV Infection
Primary: Number of Participants With the Frequency of Treatment Related Adverse Events. — 73; 10 participants
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Atherosclerotic Cardiovascular Disease
Primary: Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI…
Hepatitis C, Chronic
Primary: Incidence of Acute Myocardial Infarction (AMI) — 3.3; 5.2 Events per 1000 person years — p=.68
Alzheimer's Disease
Primary: Mini-mental State Examination (MMEE) — 12; 12 score — p=0.23
Alzheimer Disease · Dementia Alzheimers · Dementia of Alzheimer Type
Primary: Cumulative Total of New Antipsychotic Pill-days Prescribed — 12569; 25916 New antipsychotic prescription days
Pain · Opiate Addiction
Primary: Total Methadone Peak Plasma Concentration — 107.3; 315.4; 362.2 ng/mL
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
Medication Reconciliation
Primary: Number of Participants With Changes/Updates in Medication List — 101; 43 Participants — p=<0.0001